Public launch will advance Divine’s mission to put creative power back in human hands, with new creator tools, a growing community and first steps toward commercialization SAN FRANCISCO, Aug. 18, 2026 /PRNewswire/ — Divine, the 6-second looping video app with a mission to put creative…
AUSTIN, Texas, Aug. 18, 2026 /PRNewswire/ — U.S. Money Reserve, one of the nation’s largest precious metals distributors, today announced a strategic partnership with Visual Capitalist, a leading digital media publisher known for transforming complex data into clear and compelling visual…
Back by popular demand, a seasonal favorite hits shelves for a limited time as refreshed packaging and a new under-the-lid experience invite shoppers to rediscover the collection. SARASOTA, Fla., Aug. 18, 2026 /PRNewswire/ — Boar’s Head Brand®, one of the nation’s leading providers of…
ACTIVATE OTWIERA SWÓJ PIERWSZY SALON W NIEMCZECH, W BERLINIE, WE WSPÓŁPRACY Z VREX ENTERTAINMENT I SOUNDS FUN ENTERTAINMENT WINNIPEG, Manitoba, 18 sierpnia 2026 r. /PRNewswire/ — Firma Activate, oferująca najszybciej rozwijający się format rozrywki w Ameryce Północnej, otworzyła swój…
HYDERABAD, India, Aug. 18, 2026 /PRNewswire/ — According to the latest report by Mordor Intelligence, the peptide synthesis market size is estimated at USD 1.90 billion in 2026 and is projected to reach USD 2.59 billion by 2031, registering a CAGR of 6.39% during the forecast period…
Company Strengthens U.S.-Based Leadership and Investor Communications
LOS ANGELES, Aug. 17, 2026 /PRNewswire/ — Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR), today announced the appointment of Steven Przybyla as its President, effective immediately. Przybyla will also continue to serve as the Company’s Chief Legal Officer and Secretary giving the Company a senior, U.S.-based executive who will speak directly to investors about both Ispire’s regulatory strategy and its growth plan.
In his expanded role, Przybyla will lead the Company’s investor communications, working directly with the Chief Executive Officer and Chief Financial Officer on material investor relations matters. The appointment is designed to maintain continuity of senior U.S. leadership and ensure shareholders, analysts, and prospective investors have a clear, consistent point of contact. It also signals the Board’s commitment to communicating Ispire’s strategy, including its compliance-driven technology platform and its IKE Tech joint venture, clearly and consistently to the U.S. capital markets.
“Steven has been at the center of every strategic initiative we have undertaken over the past three years, from our manufacturing operations in Malaysia and intellectual property strategy to the formation and governance of IKE Tech,” said Tuanfang Liu, Chairman and CEO of Ispire. “He understands both the regulatory landscape that defines our industry and the expectations of U.S. investors. Appointing Steven as President provides us with a senior leader in the United States who can speak with authority about where this Company is going and how we intend to get there.”
“Ispire is attempting to build a new infrastructure layer for regulated nicotine economies—the hardware, the manufacturing capacity, and, through IKE Tech, the age-verification, product authentication and compliance enforcement technology that regulators and brand owners are increasingly demanding,” said Przybyla. “My priority in this role is straightforward: to make sure investors have direct, consistent access to management and a clear understanding of the assets we own, the milestones we are pursuing, and the value we believe those assets can create.”
Przybyla has served as Ispire’s Chief Legal Officer and Secretary since September 1, 2023, and will continue to serve in such capacities in addition to his new role as President. He has more than 10 years of experience in nicotine and tobacco product regulation. From April 2024 to July 2026, he served as the Company’s chosen board member and corporate secretary for its IKE Tech joint venture, which is developing point-of-use biometric age-gating, point-of-use authentication, and real-time compliance enforcement technology for regulated nicotine markets. Mr. Przybyla remains the corporate secretary for IKE Tech.
From July 2020 to April 2023, Mr. Przybyla served as General Counsel and Corporate Secretary, and subsequently as President of Hemp/Cannabis, at 22nd Century Group, Inc., a plant biotechnology company, where he helped secure the only Modified Risk Tobacco Product authorization for a combustible cigarette granted by the U.S. Food and Drug Administration to date. Previously, he was President of the Medical Division at Jushi, Inc., a multi-state cannabis operator, from 2018 to 2020; General Counsel at Dent Neurologic Group LLP from 2016 to 2018; and General Counsel at Seneca Development Corporation from 2015 to 2016. He began his career as an associate at Phillips Lytle LLP. Mr. Przybyla received his undergraduate degree in Economics from Washington & Lee University and his Juris Doctor from Columbia Law School.
About Ispire Technology Inc.
Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 400 patents worldwide. Ispire’s branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company’s cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Such risks and uncertainties that could impact these expectations and projections include, but are not limited to, risks and uncertainties regarding: the approval or rejection of any PMTA submitted by the Company; whether the Company’s IKE Tech joint venture may be successful in achieving its goals as currently contemplated, with different terms, or at all; IKE Tech’s ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company’s business strategies; and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.
Investor Contacts:
Brett Maas
Hayden IR
(646) 536-7331
[email protected]
James Carbonara
Hayden IR
(646)-755-7412
[email protected]
SOURCE Ispire Technology Inc.
Request a Demo
此合作融匯藥品級製造能力與 Ispire 的全球平台，使企業快速切入增長極其凌厲的尼古丁產品市場板塊
洛杉磯2026年5月13日 /美通社/ — Ispire Technology Inc.（「Ispire」或「本公司」）(NASDAQ：ISPR) 是電子煙技術和精準給藥領域的開拓先驅，宣佈已與全球製藥企業山東金城醫藥集團股份有限公司 (SZSE: 300233)（下稱「金城醫藥」）成立合資企業，共同生產尼古丁袋產品並推動商業銷售。
此合資項目標誌著 Ispire 進軍蓬勃發展的口含尼古丁產品板塊，將其產品組合擴展至電子煙硬件之外，並讓本公司在全球尼古丁市場中增長速度數一數二的細分市場中佔據優勢。 Grand View Research 的數據顯示，2025 年尼古丁袋市場約為 70 億美元，預計到 2033 年前將保持每年近 25% 的增長率，其市場規模或會超過 400 億美元。
Ispire 聯席行政總裁 Michael Wang 表示：「此合資企業對 Ispire 來說是一次意義重大的策略擴張。 尼古丁袋乃全球矚目的主要增長類別，是次合作令我們得以憑藉即時可用的營運實力與藥品級製造專長，迅速進軍市場。 加上我們在全球分銷及合規基礎設施方面的優勢，我們相信這將有助建立重要的新收入來源，並推動我們更全面的尼古丁平台策略。」
根據協議條款，金城醫藥將提供生產設備、技術專長及尼古丁袋原材料，以加快營運步伐，並支援近期的生產與商業化工作。 該合資企業將借助 Ispire 在精準劑量、合規監管及全球分銷上的專長，使其尼古丁袋產品在日趨白熱化的市場中別樹一幟。
金城醫藥董事長兼總裁李佳全 (Jiaquan Li) 表示：「Ispire 在生產製造及全球監管方面久經實證的卓越能力，有助我們更快邁向商業化。 藉著融合我們的製藥知識及客戶關係與 Ispire 的營運實力，我們將能佔據優勢，負責任地迅速擴大優質尼古丁袋的生產規模。」
金城醫藥是多元化的製藥公司，擁有約 3,800 名員工及全球超過 30 間附屬公司。 公司專注於醫藥中間體、活性藥物成分 (API)、成品藥及健康相關產品的研發、生產及商業化。
金城醫藥選定 Ispire 為合作夥伴，乃因 Ispire 在優質製造、營運執行力及強大的全球監管合規架構上素有佳譽。
公司預計初始生產將依賴現有的商業合作關係，並擬在口含尼古丁細分市場內開拓更多業務發展機遇，以配合其宏大的國際尼古丁平台策略。
此次拓展延續 Ispire 一貫的努力方向，藉助其製造規模、合規實力及全球分銷網絡，將產品組合多元化佈局至多種減害尼古丁產品類別。
關於 Ispire Technology Inc.
Ispire 從事品牌電子煙和大麻霧化產品的研發、設計、商業化、銷售、市場推廣和分銷。 公司旗下營運子公司在全球擁有或授權使用超過 400 項專利。 Ispire 的品牌電子煙產品以 Aspire 的名義銷售，主要透過其全球分銷網絡在全球銷售（美國、中國內地及俄羅斯除外）。 公司也與全球電子煙品牌和零售商建立原廠委託設計代工 (ODM) 合作關係。 公司的大麻產品主要以 ODM 模式向其他大麻電子煙公司銷售，並以 Ispire 品牌銷售。 Ispire 在美國、歐洲和南非銷售其大麻電子煙硬件，並已於近期在加拿大和拉丁美洲開展市場推廣活動和客戶互動。 如欲了解更多資訊，請瀏覽 www.ispiretechnology.com，或到 Instagram、LinkedIn、Twitter 及 YouTube 關注 Ispire。
前瞻性陳述
本新聞稿包含《1933 年證券法》（經修訂）第 27A 條、《1934 年證券交易法》（經修訂）第 21E 條以及《1995 年私人證券訴訟改革法》（經修訂）所指的前瞻性陳述，旨在受到上述條款所建立的安全港條款的保護。 前瞻性陳述是基於某些假設，描述公司未來的計劃、策略和預期，通常可以透過使用「相信」、「預期」、「也許」、「將」、「應該」、「會」、「可以」、「尋求」、「打算」、「計劃」、「目標」、「項目」、「估計」、「預計」、「策略」、「未來」、「可能」或其他類似術語，儘管並非所有前瞻性陳述都包含這些識別詞語。 本新聞稿除歷史事實陳述外，有關公司策略、前景、財務狀況、營運、成本、計劃和目標的所有陳述均為前瞻性陳述。 可能導致公司實際業績和財務狀況與前瞻性陳述中所示業績和財務狀況有重大差異的重要因素。 此類前瞻性陳述包括但不限於風險和不確定性，包括以下方面：公司能否成功重返美國電子尼古丁傳送系統市場；公司提交的任何煙草產品上市前申請 (PMTA) 是否獲得批准或拒絕；公司能否成功落實進一步拓展非洲市場的計劃；公司與 Touch Point Worldwide Inc.（以 Berify 名義開展業務）和 Chemular Inc.（下稱「合資企業」）的合資企業能否按照目前設想的方式、以不同的條款或根本無法實現目標；合資企業在電子煙技術領域進行創新或開發尼古丁電子煙裝置的年齡限制或年齡驗證技術的能力；公司及時收回應收賬款的能力；公司的商業策略；公司向 Ispire ONE™ 進行市場推廣的能力；Ispire ONE™ 實現其目標的成功情況；客戶能否獲得 Ispire ONE™ 的預期收益以及其產品在市場是否成功；Ispire ONE™ 被證明是安全；以及「風險因素」、「管理階層對財務狀況和經營業績的討論與分析」、「關於前瞻性陳述的警示性說明」中所述的風險和不確定性，以及 Ispire 截至 2025 年 6 月 30 日止年度的 10-K 表格年度報告和 Ispire 隨後向美國證券交易委員會提交的任何文件中所述的其他風險。 前瞻性陳述不應視作對未來事件的預測。 本新聞稿中所作的前瞻性陳述僅與本新聞稿發佈之日發生的事件或資訊有關。 除適用法律另有規定外，我們不承擔在聲明發佈之日後因新資訊、未來事件或其他原因而更新或修改任何前瞻性陳述的義務，也不承擔反映意外事件發生的義務。 閱讀本新聞稿時應理解，我們未來的實際業績可能與我方預期有重大差異。
投資者關係聯絡人：
Brett Maas
Hayden IR
(646) 536-7331
[email protected]
James Carbonara
Hayden IR
(646)-755-7412
[email protected]
公共關係聯絡人：
Ellen Mellody
+1-570-209-2947
[email protected]
SOURCE Ispire Technology Inc.
今回の提携により、医薬品グレードの製造技術と Ispireのグローバル・プラットフォームを組み合わせ、最も急成長しているニコチン分野への参入を加速させる
ロサンゼルス, 2026年5月14日 /PRNewswire/ — ベイプ技術と精密な投与技術における先駆者であるIspire Technology Inc. (「Ispire」または「当社」）（NASDAQ：ISPR）は、グローバル製薬企業であるShandong Jincheng Pharmaceutical Group Co., Ltd. (SZSE：300233）（「Jincheng Pharma」）と、ニコチンポーチ製品の製造および販売を目的とした合弁事業契約を締結したと発表しました。
この合弁事業により、Ispireは急成長を遂げている経口ニコチン市場に参入することとなり、同社の事業ポートフォリオを電子タバコ機器の枠を超えて拡大させるとともに、世界的なニコチン市場において最も成長著しいセグメントの一つに同社を位置づけることとなります。Grand View Researchによると、ニコチンパウチの市場規模は2025年に約70億ドルで、2033年まで毎年25％近い成長率で成長し、400億ドルを超える可能性があると予測されています。
「この合弁事業は、Ispireにとって意義のある戦略的拡大です」と、Ispireの共同最高経営責任者（CEO）であるMichael Wangは述べています。「ニコチンパウチは世界的に成長する主要なカテゴリーであり、この提携により、即座の操業能力と医薬品グレードの製造専門知識をもって市場に参入することができます。当社の世界的な流通・規制インフラと組み合わせることで、新たに重要な収益源を構築し、より広範なニコチン・プラットフォーム戦略をさらに推進することができると確信しています。」
同契約に基づき、Jincheng Pharmaは製造設備、技術的専門知識、ニコチンパウチ用原材料を提供し、迅速な生産体制の拡大を可能にするとともに、短期的な生産および商品化を支援します。この合弁会社は、Ispireが持つ精密な投与量管理、規制順守、およびグローバルな流通網という強みを活かし、競争が激化する市場において、同社のニコチンポーチ製品を差別化していくものと期待されています。
「Ispireの実績ある優れた製造能力とグローバルな規制対応能力が、当社の製品化への道を加速させます」と、Jincheng Pharmaの会長兼社長であるJiaquan Liは述べています。「当社の医薬品に関する専門知識と顧客との関係を、Ispireの運営能力と組み合わせることで、高品質なニコチンパウチの生産を迅速かつ責任を持って拡大することができます。
Jincheng Pharmaは、従業員約3,800人、世界各地に30以上の関連会社を持つ多角的な製薬会社です。当社は医薬品中間体、医薬品原薬（API）、完成医薬品、健康関連製品の研究、開発、製造、商業化に従事しています。
Jinchengは、高品質の製造、業務遂行、強力なグローバル規制コンプライアンス・インフラストラクチャに対するIspireの評判に基づいて、Ispireをパートナーとして選択しました。
当社は、既存の取引関係が初期生産を支えると見込んでおり、より広範な国際的なニコチンプラットフォーム戦略の一環として、経口ニコチン分野におけるさらなる事業開発の機会を追求していく方針です。
この拡大は、製造規模、コンプライアンス能力、グローバルな流通網を活用しながら、複数のリスク低減型ニコチンフォーマットで製品ポートフォリオを多様化するという、Ispireの継続的な取り組みに基づくものです。
Ispire Technology Inc.について
Ispire は、ブランド電子タバコおよび大麻用ベイピング製品の研究開発、設計、商品化、販売、マーケティング、ならびに流通に従事しています。当社の事業子会社は、世界で400件を超える特許を所有またはライセンスしています。Ispireのブランド電子タバコ製品は「Aspire」の名称で販売されており、主に同社のグローバル流通ネットワークを通じて、世界各国（米国、中華人民共和国、ロシアを除く）で販売されています。当社はまた、世界中の電子タバコブランドや小売業者とのODM（受託設計製造）関係にも取り組んでいます。当社の大麻製品は、Ispireのブランド名で、主にODMベースで他の大麻ベイプ企業に販売しています。Ispireは、米国、欧州、南アフリカで大麻用ベイプハードウェアを販売しており、最近ではカナダやラテンアメリカでもマーケティング活動と顧客開拓を開始しています。 詳しくは www.ispiretechnology.comをご覧いただくか、 Instagram、 LinkedIn、 Twitter、 YouTubeでIspireをフォローしてください。
将来予想に関する記述
本プレスリリースには、1933年証券法（改正後、以下「証券法」）第27A条、1934年証券取引法（改正後）第21E条、および1995年私募証券訴訟改革法（改正後）に基づく「セーフハーバー」規定により保護されることを意図した将来予想に関する記述が含まれています。将来見通しに関する記述は、一定の仮定に基づき、当社の将来の計画、戦略、期待を述べたものです。一般的には、「信じる」「期待する」「かもしれない」「だろう」「すべきである」「であろう」「できる」「努める」「意図する」「計画する」「目標とする」「見積もる」「予想する」「戦略」「将来」「可能性が高い」などの将来見通しに関する用語、またはその他の類似の用語を使用することで識別できます。ただし、すべての将来見通しに関する記述にこれらの識別語が含まれているわけではありません。本プレスリリースに記載された、当社の戦略、見通し、財務状況、事業運営、コスト、計画および目標に関する記述のうち、過去の事実に関するものを除くすべては、将来見通しに関する記述です。当社の実際の業績および財務状況が将来見通しに関する記述で示された内容と大きく異なる可能性のある重要な要因には、以下のものが含まれます。そのような将来見通しに関する記述には、以下を含むがこれらに限定されないリスクや不確実性が含まれます。当社が米国のENDS市場への再参入に成功するかどうか、当社が提出したPMTAの承認または却下、当社がアフリカ市場へのさらなる進出計画を成功させられるかどうか、Touch Point Worldwide Inc.（d/b/a Berify）およびChemular Inc.との合弁事業（以下「合弁事業」）がその目標を達成できるかどうか（異なる条件で、またはまったく達成できないかどうか）、合弁事業が電子タバコ技術分野で革新を起こす能力、またはニコチンベイピングデバイス用の年齢制限技術もしくは年齢確認技術を開発する能力、当社の売掛金を適時に回収する能力、当社の事業戦略、当社がIspire ONE™を販売する能力、Ispire ONE™がその目標を達成できるかどうか、顧客がIspire ONE™の期待される利益を得る能力および市場における製品の成功、Ispire ONE™の安全性の証明、ならびに「リスク要因」、「経営陣による財務状況および経営成績の分析」、「将来見通しに関する記述に関する注意事項」に記載されているリスクと不確実性、および2025年6月30日を期末とするIspireのForm 10-K年次報告書、ならびにIspireがSECに提出するその後の提出書類に記載されている追加のリスクが含まれます。将来見通しに関する記述を将来の出来事に関する予測として信頼すべきではありません。本プレスリリースにおける将来見通しに関する記述は、本リリースに記載された日付時点の出来事または情報のみに関連しています。当社は、適用法により求められる場合を除き、新たな情報、将来の出来事、またはその他の理由により、本プレスリリースに記載された日付以降に将来見通しに関する記述を更新または修正する義務を一切負いません。本プレスリリースは、当社の将来の実際の業績が当社の予想と大きく異なる可能性があることを理解した上でお読みください。
IR 連絡先：
Brett Maas
Hayden IR
(646) 536-7331
[email protected]
James Carbonara
Hayden IR
(646)-755-7412
[email protected]
PRに関するお問い合わせ先：
Ellen Mellody
+1-570-209-2947
[email protected]
ロゴ – https://mma.prnewswire.com/media/2771569/Ispire_Technology_Logo.jpg
SOURCE Ispire Technology Inc.
Partnership combines pharmaceutical-grade manufacturing with Ispire’s global platform to accelerate entry into one of the fastest-growing nicotine segments
LOS ANGELES, May 12, 2026 /PRNewswire/ — Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced that it has entered into a joint venture with Shandong Jincheng Pharmaceutical Group Co., Ltd. (SZSE: 300233) (“Jincheng Pharma”), a global pharmaceutical company, to manufacture and commercialize nicotine pouch products.
The joint venture marks Ispire’s entry into the rapidly expanding oral nicotine category, broadening its portfolio beyond vaping hardware and positioning the Company in one of the fastest-growing segments of the global nicotine market. According to Grand View Research, the nicotine pouch market was approximately $7 billion in 2025 and is projected to grow at nearly 25% annually through 2033, potentially exceeding $40 billion.
“This joint venture represents a meaningful strategic expansion for Ispire,” said Michael Wang, Co-Chief Executive Officer of Ispire. “Nicotine pouches are a major global growth category, and this partnership enables us to enter the market with immediate operational capability and pharmaceutical-grade manufacturing expertise. Combined with our global distribution and regulatory infrastructure, we believe this positions us to build a significant new revenue stream and further advance our broader nicotine platform strategy.”
Under the terms of the agreement, Jincheng Pharma will contribute manufacturing equipment, technical expertise, and nicotine pouch materials, enabling a rapid operational ramp-up and supporting near-term production and commercialization. The joint venture is expected to leverage Ispire’s strengths in precision dosing, regulatory compliance, and global distribution to differentiate its nicotine pouch offerings in an increasingly competitive market.
“Ispire’s proven manufacturing excellence and global regulatory capabilities accelerate our path to commercialization,” said Jiaquan Li, Chairman and President of Jincheng Pharma. “By combining our pharmaceutical expertise and customer relationships with Ispire’s operational capabilities, we are well positioned to scale high-quality nicotine pouch production quickly and responsibly.”
Jincheng Pharma is a diversified pharmaceutical company with approximately 3,800 employees and more than 30 affiliated companies worldwide. The company is engaged in the research, development, production, and commercialization of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), finished pharmaceutical products, and health-related products.
Jincheng selected Ispire as its partner based on Ispire’s reputation for high-quality manufacturing, operational execution, and strong global regulatory compliance infrastructure.
The Company expects initial production to be supported by existing commercial relationships and intends to pursue additional business development opportunities within the oral nicotine segment as part of its broader international nicotine platform strategy.
This expansion builds on Ispire’s ongoing efforts to diversify its product portfolio across multiple reduced-risk nicotine formats while leveraging its manufacturing scale, compliance capabilities, and global distribution network.
About Ispire Technology Inc.
Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 400 patents worldwide. Ispire’s branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company’s cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company’s joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the “Joint Venture”) may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture’s ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company’s ability to collect its accounts receivable in a timely manner; the Company’s business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™’s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.
IR Contact:
Brett Maas
Hayden IR
(646) 536-7331
brett@haydenir.com
James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com
PR Contact:
Ellen Mellody
+1-570-209-2947
ispire@kcsa.com
SOURCE Ispire Technology Inc.
Partnership combines pharmaceutical-grade manufacturing with Ispire’s global platform to accelerate entry into one of the fastest-growing nicotine segments
LOS ANGELES, May 12, 2026 /PRNewswire/ — Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced that it has entered into a joint venture with Shandong Jincheng Pharmaceutical Group Co., Ltd. (SZSE: 300233) (“Jincheng Pharma”), a global pharmaceutical company, to manufacture and commercialize nicotine pouch products.
The joint venture marks Ispire’s entry into the rapidly expanding oral nicotine category, broadening its portfolio beyond vaping hardware and positioning the Company in one of the fastest-growing segments of the global nicotine market. According to Grand View Research, the nicotine pouch market was approximately $7 billion in 2025 and is projected to grow at nearly 25% annually through 2033, potentially exceeding $40 billion.
“This joint venture represents a meaningful strategic expansion for Ispire,” said Michael Wang, Co-Chief Executive Officer of Ispire. “Nicotine pouches are a major global growth category, and this partnership enables us to enter the market with immediate operational capability and pharmaceutical-grade manufacturing expertise. Combined with our global distribution and regulatory infrastructure, we believe this positions us to build a significant new revenue stream and further advance our broader nicotine platform strategy.”
Under the terms of the agreement, Jincheng Pharma will contribute manufacturing equipment, technical expertise, and nicotine pouch materials, enabling a rapid operational ramp-up and supporting near-term production and commercialization. The joint venture is expected to leverage Ispire’s strengths in precision dosing, regulatory compliance, and global distribution to differentiate its nicotine pouch offerings in an increasingly competitive market.
“Ispire’s proven manufacturing excellence and global regulatory capabilities accelerate our path to commercialization,” said Jiaquan Li, Chairman and President of Jincheng Pharma. “By combining our pharmaceutical expertise and customer relationships with Ispire’s operational capabilities, we are well positioned to scale high-quality nicotine pouch production quickly and responsibly.”
Jincheng Pharma is a diversified pharmaceutical company with approximately 3,800 employees and more than 30 affiliated companies worldwide. The company is engaged in the research, development, production, and commercialization of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), finished pharmaceutical products, and health-related products.
Jincheng selected Ispire as its partner based on Ispire’s reputation for high-quality manufacturing, operational execution, and strong global regulatory compliance infrastructure.
The Company expects initial production to be supported by existing commercial relationships and intends to pursue additional business development opportunities within the oral nicotine segment as part of its broader international nicotine platform strategy.
This expansion builds on Ispire’s ongoing efforts to diversify its product portfolio across multiple reduced-risk nicotine formats while leveraging its manufacturing scale, compliance capabilities, and global distribution network.
About Ispire Technology Inc.
Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 400 patents worldwide. Ispire’s branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company’s cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company’s joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the “Joint Venture”) may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture’s ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company’s ability to collect its accounts receivable in a timely manner; the Company’s business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™’s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.
IR Contact:
Brett Maas
Hayden IR
(646) 536-7331
[email protected]
James Carbonara
Hayden IR
(646)-755-7412
[email protected]
PR Contact:
Ellen Mellody
+1-570-209-2947
[email protected]
SOURCE Ispire Technology Inc.
